SYS6012 (secukinumab biosimilar)
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 06, 2025
A Randomized, Double-blind, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of SYS6012 VS secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis
(ChiCTR)
- P3 | N=394 | Completed | Sponsor: Shanghai Skin Disease Hospital; Shanghai Skin Disease Hospital
New P3 trial • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis
1 to 1
Of
1
Go to page
1